Funding Announcements

Week of October 26

DOD Breast Cancer Research Program Awards

Pre-Application Deadline: November 18, 2009
More Information

The Department of Defense Breast Cancer Research Program (BCRP) has released the “Era of Hope Scholar Awards” and “Postdoctoral Fellowship Awards” Program Announcements and is open for submissions.  The following funding opportunity information may interest newer faculty and postdoctoral researchers in bio-life, basic, bio-engineering, epidemiology, behavioral, and social scientists considering innovative research in breast cancer research at the University of Colorado Health Sciences Center. 

Era of Hope Scholar Awards 

The Era of Hope Scholar Award supports individuals who have high potential for innovation in breast cancer research early in their careers. Nominees for this award should be exceptionally talented, early-career scientists who have demonstrated that they are the “best and brightest” in their field(s) through extraordinary creativity, vision, and productivity.  They also should exhibit strong potential for leadership in the breast cancer research community and be able to articulate a vision for the eradication of breast cancer.  Experience in breast cancer research is not required; however, the application should focus on breast cancer research, and the PI must commit at least 50% of his/her full-time professional effort during the award period to breast cancer research.  Principal Investigators (PIs) must be independent, non-mentored investigators within 6 years of their last mentored position.

A maximum of $2,500,000 for direct costs over a 5 year maximum performance period, plus indirect costs as appropriate, is offered.  The CDMRP expects to allot approximately $12M of the $150M FY09 BCRP appropriation to fund approximately 3 Era of Hope proposals, depending on the quality and number of proposals received.

Postdoctoral Fellowship Awards

Postdoctoral Fellowship Awards support exceptionally talented recent medical or other doctoral graduates in their pursuit of innovative, high-impact breast cancer research during their postdoctoral training and allows them to obtain the necessary experience for an independent career at the forefront of breast cancer research.  The postdoctoral trainee is considered the Principal Investigator (PI) and, as such, should write the project narrative with appropriate direction from the mentor.  While the PI is not required to have previous experience in breast cancer research, this application must focus on breast cancer research.  Applications must provide evidence of the PI’s potential for success in becoming an independent breast cancer researcher based on his/her qualifications, characteristics, achievements, and letters of recommendations.  The mentor (or co-mentor, if applicable) must possess the appropriate expertise and experience in breast cancer, to include peer reviewed breast cancer funding and publications, and clearly demonstrate a commitment to guiding the PI’s research and training.  As of the application submission deadline, the PI must have been in the laboratory in which this research is to be performed for no more than 2 years, and he/she must have a total of less than 4 years of postdoctoral research experience (excluding clinical residency or fellowship training).

A maximum of $300,000 ($100,000 per year) for direct costs over a 3 year maximum performance period, plus indirect costs as appropriate, is offered.  The CDMRP expects to allot approximately $8M of the $150M FY09 BCRP appropriation to fund approximately 25 Postdoctoral Fellowship applicants, depending on the quality and number of proposals received.

NIH K-12 Building Interdisciplinary Research Careers in Women's Health (BIRCWH) at UC Denver

Letter of Intent Deadline: November 1, 2009
Deadline: November 30, 2009 at 5:00 PM Mountain Time

I.    General Information

  • Scholars will be considered who are pursuing a research career in one of these areas of women’s health
  • Pregnancy, fetal programming, or lactation;
  • Aging, cardiovascular disease, diabetes or obesity;
  • Women’s cancers.   
    • Clinical Scholars must hold the MD,DO, or PhD in nursing, have completed their clinical training, and demonstrate a commitment to pursuing a successful career involving research in women’s health.
    • PhD Scholars must have completed a postdoctoral fellowship and demonstrate a commitment to pursuing a successful career involving research in women’s health.
    • Candidates must be U.S. citizens, nationals or permanent resident aliens. 
    • Applicants who are eligible to become faculty and junior faculty who have just initiated an academic career are eligible to apply. 

A two year award designed to support junior faculty who are interested in a career in women's health research will be available, January 1, 2010 . One position is available. Salary and some program support will be provided to the successful applicant for two years. Interested applicants are encouraged to apply following the attached instructions. A letter of intent is due November 1; the application is due at 5:00 PM on November 30. One award is expected to be made starting January 1.

II.       Underrepresented Minorities

Underrepresented minorities who meet the program requirements are particularly urged to apply.

III.       Application Requirements

Application requirements include significant research experience for all applicants, completion of a clinical fellowship or completion of at least two years of postdoctoral training for PhD Scholar candidates. 

The application must include:

  • Curriculum vitae including training history, awards, bibliography, presentations.
  • A detailed personal statement (maximum 2 pages) demonstrating a commitment to a career in women’s health research, outlining personal strengths that will insure success in this endeavor, and stating why the individual should be chosen for the program. Applicants are urged to choose an approved BIRCWH mentor (see Appendix 1 below for list) and explain why they have chosen the mentor and how they will work together.  If an applicant wishes to work with a primary mentor who is not on the list, that individual must work in one of the areas outlined above.  The Program Director will assist in obtaining NIH approval for an appropriate mentor not already on the list below.
  • A description of the applicant’s research experience (maximum 3 pages). The section should describe prior projects/experience that demonstrate the applicant’s ability to perform clinical, translational, epidemiological or basic research.
  • A description of the steps the applicant expects to take to become an independent investigator in the area of women’s health research (maximum 3 pages).  Potential research projects should be described as well as any necessary course work. 
  • A letter from the applicant’s department chair or division chief confirming that the applicant will have at least 75% time for pursuit of his/her research program.    In addition this letter should provide assurance that the applicant is entering into a tenure eligible position and set forth the other means by which the department/division will support the applicant’s proposed research program.
  • A minimum of three (but not more than five) letters of reference sent directly to the BIRCWH program office (address below) demonstrating evidence of the applicant’s strength in or support for the proposed areas of research. One of these letters should come from the applicant’s proposed mentor.

All application materials except letters of reference should be submitted together by email to Barb Morgan Barb.Morgan@ucdenver.edu

Letters of reference should clearly state the name of the applicant and be submitted directly to the above address.

IV.     Review Criteria

Criteria to be used for selection of scholars include:

1) Excellence of training and, for clinician-scientists, board eligibility or completion;

2) Evidence of a high level of scholarship;

4) Clarity of the statement of career direction and goals;

5) Letters of recommendation

6) Clarity of the vision of both applicant and mentor as to career goals and commitment to research in women’s health

7) Clear future career support from the Department Chair. 

Each application will be pre-reviewed by the Program Directors for compliance with application rules.  Copies of all accepted applications will be available to all members of the Selection Committee, and each candidate will be evaluated in detail by at least two members, with written reviews being provided.  Review assignments will be made by the Program Directors.  After full Selection Committee discussion, NIH-style priority scores will be assigned by secret ballot, and the scores averaged and ranked.  Any Selection Committee member with a conflict of interest will leave the room during the entire review and discussion of the applicant.  Applicants will be and notified in writing of the outcome of the review and sent edited written reviews as soon as feasible.  Candidates who are not selected as BIRCWH Scholars are encouraged to meet with the Program Directors to review their application to determine whether and how it may be strengthened for re-application or application for other K awards.

Appendix 1: BIRCWH Mentors:

Focus Areas

Faculty Mentors

Fetal Programming, Pregnancy, Lactation

 

 

Dana Dabelea, MD, PhD, Preventive Medicine;

Jacob Friedman,PhD, Pediatrics;

Henry Galan, MD, Section Chief, Ob/Gyn;

Mark Geraci,MD, Division Head, Pulmonary;

William Hay Jr, MD, Pediatrics;

Edward Janoff, MD, Division Head, Infectious Disease;

Patti Thureen, MD, Pediatrics

Margaret Wierman, MD, VA Division Chief, Endocrinology

Aging, CV Disease,

Diabetes, Obesity

 

 

Chris DeSouza,PhD, Applied Physiology, Boulder

Robert Eckel, MD, Endocrinology, GCRC Director;

Wendy Kohrt, PhD, Geriatrics;

Leslie Leinwand, PhD, MCDB;

Jill Norris,PhD, Preventive Medicine;

Judith Regensteiner,PhD, Cardiology/General Internal Medicine

Jane Reusch, MD, Endocrinology

Women’s Cancers

 

 

Steven Anderson, PhD, Pathology;

Tim Byers, MD, MPH, Cancer Epidemiology

Kathryn Horwitz, PhD, Endocrinology/Breast Cancer;

Heide Ford, PhD,  Ob/Gyn;

Arthur Gutierrez-Hartman, MD, Endocrinology;

Andrew Thorburn, PhD, Pharmacology

Questions about the program should be addressed to judy.regensteiner@uchsc.edu, Principal Investigator and Program Director for the Colorado BIRCWH or peggy.neville@uchsc.edu, Co-Program Director for the Colorado BIRCWH

Week of October 12

Lymphoma Research Foundation--3 year Follicular Lymphoma grant

Deadline: January 12, 2010
More Information

The Lymphoma Research Foundation (LRF) Follicular Lymphoma Consortium seeks proposals for clinical studies in follicular lymphoma (FL). Applications to this initiative must involve either clinical trials, correlative research associated with a clinical trial, or be based on the study of primary FL patient samples.  Applications may be for a time frame of up to 3 years duration for a budget of up to $150,000 total costs per year.

The proposed study should investigate the pathogenesis, diagnosis, or treatment of follicular lymphoma.  Examples of eligible projects include:

  • Molecular and/or genetic profiling of patient-derived samples
  • Identification of biomarkers
  • Immunological/immunotherapy studies
  • Experimental therapeutics
  • Correlative studies for clinical trials

IASLAC Fellowship Award

Deadline: January 10, 2010
More Information

The IASLC is proud to announce a continuation and expansion of the IASLC Fellowship and Young Investigators Programs:

  • IASLC Lung Cancer Fellowship Award/Young Investigators Award- 2 years duration
  • IASLC/PCF Prevent Cancer Foundation Fellowship Award -2 years duration
  • IASLC/National Lung Cancer Partnership Fellowship Award- 2 years duration

Overall there are 18 potential awards for two years each.  There are awards in prevention and translational lung cancer research that are jointly sponsored with the Prevent Cancer Foundation, (PCF), through educational grants from Eli Lilly.  There are unrestricted awards in any field of lung cancer research supported by educational grants from National Lung Cancer Partnership, GlaxoSmithKline, Sanofi-Aventis, AstraZeneca, Celgene, Pfizer, Eli Lilly, and OSI.

This year 6 new unrestricted awards of $40,000 each year for 2 years are available for competition.  We are now requesting application for these Fellowships and Young Investigator awards to be awarded in 2010.  The goal is to reward scientific excellence and to encourage innovative investigations in the field of lung cancer prevention research and translational research with a potential impact on the management of lung cancer.  The applications will be evaluated by a Scientific Review Panel; the deadline for submission of the application is January 10, 2010.  A decision on applications will be reached by March 2010.

Week of October 5

Association for Research of Childhood Cancer Research Grants

Deadline: January 1, 2010
More Information

The purpose of the Association For Research of Childhood Cancer grant awards is to provide funding for basic science and clinical projects related to the goal of advancing knowledge in Pediatric and Adoles cent cancers. All grants are peer reviewed by the Medical/Scientific Advisory Board. Funding decisions are made by the AROCC Board based on the recommendations of the Medical/Scientific Advisory Board and the availability of funds.

The Association for Research of Childhood Cancer does NOT provide funding for travel, photocopying, general office costs and grant or salary overhead costs and fringe benefits.It is the responsibility of the applicant to obtain all appropriate administrative clearances, including if necessary, Institutional Review Board approval. Deadline for application is January 1st for awards in June of the following year. A complete report of research activities including publications and other grants resulting from the work must be submitted within three (3) months of grant ending or termination.

We provide support for multiple, one-year "seed type" grants (not to exceed $30,000) addressing basic science and/or clinical research in areas directly or indirectly related to research issues in Pediatric or Adoles cent cancer research. The number of such awards will vary depending on availability of funds in any granting period.

NIH Community Networks Program (CNP) Centers for Reducing Cancer Disparities Through Outreach, Research and Training       RFA-CA-09-032 (U54 grant)

Letter of Intent Deadline: November 15, 2009
Grant Deadline: December 15, 2009 (Only one grant per institution is allowed. Please notify Dr. Traystman if you are interested)
More Information

Week of September 28

ACS IRG UCCC Seed Grants

Deadline: November 30, 2009 5 PM MST (No Exceptions!)

The purpose of this grant program is to support the development of exceptional research projects that will help lead to the conquest of cancer and will further the objectives of the UCCC.  Funding for these grants is made possible from several sources, including:

      1) the American Cancer Society Institutional Research Grant (ACS IRG 57-001-50)
      2) the University of Colorado Cancer Center (UCCC) unrestricted gift funds, and
      3) development funds under the UCCC Cancer Center Support Grant (P30 CA046934).   

Studies in all areas of cancer research (laboratory, clinical, prevention and control, and psychosocial cancer research) will be considered for funding.

ACS IRG GRANTS

The spirit of these grants is to entice young faculty to pursue cancer-related research problems.  ACS IRG grants are reserved for those applicants who are in their first few years as junior faculty members (instructors and assistant professors) and who are in the process of establishing independent cancer research programs.  Applicants cannot have received prior, or hold current, major funding from a national peer-reviewed source (R01, R21, R25, NSF, ACS, AHA, DOD, etc.).  Priority will be given to those applications which demonstrate promise to lead to further funding through conventional support mechanisms.

ACS IRG funds can be used to support project-related expenses only.  Funds cannot be used for salary support for the PI.  Applications for novel clinical projects and for community-based projects are particularly encouraged in addition to basic science projects.

Awards will be made for a maximum of $30,000 for one year, beginning January 1, 2010 .  These grants are not renewable, but a one-year no-cost extension may be requested.

UCCC Seed Grants(funded by UCCC gift or P30 development funds)

The UCCC funds will be used to support innovative pilot projects that have not received any prior funding.  These projects must explore new areas of cancer-related research distinct from the investigator’s current research goals.  In addition, the UCCC would like to increase the number of funded clinical, prevention and control, and psychosocial pilot grants in order to obtain a relatively balanced portfolio of support.  To that end, grants for novel clinical projects and for community-based projects are particularly encouraged.

An emphasis of the UCCC has been to foster the development of successful multi-disciplinary and inter-institutional collaborations involving two or more UCCC members.  Applications demonstrating new collaborative efforts with a strong translational aspect to the work will be given the highest consideration.  As well, priority will be given to those applications which demonstrate promise to lead to further funding through conventional support mechanisms as well as those projects designed to explore highly innovative, unconventional or high-risk approaches to the cancer problem. 

Scientists and clinicians who are members of the UCCC are eligible to apply for a UCCC seed grant.  To be eligible for UCCC Funding, faculty who are not UCCC members will either collaborate with a UCCC member or will have filed an application for membership in the UCCC prior to the December 1 deadline.  Multi-disciplinary collaborations are defined as projects involving two or more UCCC members from different disciplines.  Inter-institutional collaborations are defined as projects involving two or more UCCC members from different UCCC consortium institutions.

UCCC funds can be used to support project-related expenses only.  Funds can provide for partial salary support for junior faculty members who are awarded seed grants and/or research technicians involved in the project.  Other, non-personnel expenses appropriate to the project are also acceptable budget items.  The use of the UCCC Shared Resource Facilities (Cores) to support each research effort is required and must make up >50% of the budget request.  If no core facility use is proposed, the budget justification must include a strong rationale for this.

Seed grant awards will be made for a maximum of $20,000 for one year, beginning February 1, 2010 or later.

Research Fellowships

Fellowships are designed to provide matching funds for postdoctoral trainees (either PhD or MD) of UCCC members.  Awards up to $10,000 will be made to support the UCCC fellow.  Funds may be used for the fellow’s salary and/or other expenses related to the fellow’s research.  Applications for these funds must be prepared by the fellow.

Awards will be made for one year beginning February 1, 2010 or later.

UCCC Collaborative Translational Award

To emphasize the importance of multi-disciplinary and inter-disciplinary collaborations, the UCCC will fund a collaborative translational pilot award.  Projects for this award must include the participation of at least two UCCC members, preferably a clinical and a basic scientist, and must be a translational research project.

UCCC funds can be used to support project-related expenses only.  Funds can provide for partial salary support for junior faculty members and/or research technicians involved in the project, and/or other types of project-related expenses.  The use of the UCCC Shared Resource Facilities (Cores) to support each research effort is strongly encouraged.  If no core facility use is proposed, the budget justification must include a strong rationale for this.

Collaborative translational pilot awards will be made for a maximum of $50,000 for one year, beginning February 1, 2010 or later.

UCCC – Special emphasis AWARDS

The UCCC has funds available periodically to support innovative studies in areas of special emphasis.  Currently, projects focused on head and neck cancers are encouraged as part of ongoing planning for a SPORE in head and neck cancers.  Funds can be used to support project-related expenses only.  Allowable expenses include salary support for the PI, fellows and/or lab or clinical technicians involved in the project; laboratory or clinical expenses related to the project; and/or equipment needed for the project.   Awards will be made for one year beginning February 1, 2010 or later.

APPLICATIONS

Guidelines and the application form are available by e-mail request to connie.bair@ucdenver.edu.

UCCC Membership Application forms are available by e-mail request to suzanne.smith@ucdenver.edu

 

DOD Lung Cancer Biospecimen Resource Network (LCBRN) Award

Pre-application Deadline: December 23, 2009
More Information

The FY09 Lung Cancer Research Program has released the Program Announcement/Funding Opportunity for the Lung Cancer Biospecimen Resource Network (LCBRN) Award.  The LCBRN award is intended to provide infrastructure support for the development of a lung cancer biospecimen resource that will facilitate the collection, processing, annotation, storage, and distribution of high-quality human lung cancer biospecimens through a collaborative network across multiple institutions.  The LCBRN will consist of a Coordinating Center that will also function as a biospecimen resource site and a minimum of two additional Biospecimen Resource Sites that will be jointly responsible for developing the biospecimen resource network for lung cancer research.  The Coordinating Center and Biospecimen Resource Sites must submit a single application.

The proposed LCBRN must collect, process, annotate, store, and distribute human lung cancer biospecimens that support two or more of the Areas of Emphasis listed below:

  • Identification or development of non-invasive or minimally invasive tools to improve the detection of the initial stages of lung cancer.
  • Identification and development of tools for screening or early detection of lung cancer. Screening may include, but is not limited to, computed tomography scans, X-rays, other imaging, biomarkers, genetics/genomics/proteomics, and assessment of risk factors.
  • Understanding the molecular mechanisms that lead to clinically significant lung cancer.
  • Identification of the mechanisms that lead to the development of the various types of lung cancer.
  • Identification of innovative strategies for prevention and treatment of early lung cancer.
  • Understanding predictive and prognostic markers to identify responders and non-responders.
  • Understanding acquired resistance to treatment.

National Marrow Donor Program
The Amy Strelzer Manasevit Research Program for the Study of Post-Transplantation Complications

Deadline: November 6, 2009
More Information

Be The Match Foundation and the National Marrow Donor Program (NMDP) are pleased to announce that applications for the Amy Strelzer Manasevit Research Program are available.  This research program is directed toward scientists and clinicians early in their careers and is intended to advance the understanding of events occurring after allogeneic hematopoietic stem cell transplantation.  The program is dedicated to the memory of Amy Strelzer Manasevit and is made possible through the generosity and commitment of her family and friends.

The research proposal must address issues arising after allogeneic hematopoietic cell transplantation.  Proposals must describe pre-clinical investigations that are laboratory-based human or animal studies designed to test the mechanisms, safety, and efficacy of an intervention prior to or in conjunction with its application in humans.  One award will be made for a maximum of $240,000 in research support divided over three years. Payments will be made in segments; upon receipt of grant, at six month reporting milestones and upon receipt of final report.

National Institute of Environmental Health Science (NIEHS)

Deadline: November 30, 2009
More Information

The National Institute of Environmental Health Science (NIEHS) and the National Cancer Institute (NCI) intend to promote a new initiative by publishing a set of Requests for Applications (RFA) to solicit applications for research on the Breast Cancer and the Environment Research Program (BCERP). These activities will support parallel ongoing epidemiological investigations and new laboratory and epidemiological studies on environmental influences on breast cancer risk. The BCERP is among a select few NIH projects supporting transdisciplinary research on the interaction of environmental factors, including chemical, physical, biological, and social environmental, with genetic factors within windows of susceptibility throughout a woman’s lifespan.

Sarcoma Foundation of America Research Grants

Deadline: January 31, 2010

The Sarcoma Foundation of America is pleased to announce its annual call for proposals. Grants of $25,000 are available to cover equipment and supplies in support of research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human sarcomas. Grants will be reviewed by the SFA Medical Advisory Board immediately following the application deadline of January 31, 2010. Applicants will be notified on or before April 10th as to the award decision for their proposal. The funds awarded will be then available for research by June 1, 2010.

Applications must be submitted using the official SFA Grant Application. The application forms, including bio sketch(es), and references, must not exceed 10 pages. Biosketches, not CVs, are specifically requested to minimize submission length. Preliminary data to support the application is acceptable, but the 10-page limit is not to be exceeded. Do not submit manuscripts or journal articles. Application submissions exceeding 10 pages in length will not be considered.

Proposals are to be submitted as follows:

Electronic Submission: sfagrants@curesarcoma.org   OR

Mail to:
Sarcoma Foundation of America
9884 Main Street
Damascus , MD 20872

Week of September 21

EUREKA Grant

Deadline: Nov. 24, 2009
More Information

This FOA solicits Research Project Grant (R01) applications from institutions/organizations proposing exceptionally innovative research on novel hypotheses or difficult problems, solutions to which would have an extremely high impact on biomedical or biobehavioral research that is germane to the mission of one or more of the participating NIH Institutes. This FOA is for support of new projects, not continuation of projects that have already been initiated. It does not support pilot projects, i.e., projects of limited scope that are designed primarily to generate data that will enable the PI to seek other funding.

Week of September 14

Sidney Kimmel Foundation for Cancer Research

Deadline: Dec. 2, 2009
More Information

The Sidney Kimmel Foundation for Cancer Research funds the Kimmel Scholars Program, which each year, through a distinguished medical board of advisors, provides research grants to the nation's most promising young cancer researchers. To date there have been 172 recipients of these awards. The goal of the grant program is to improve the basic understanding of cancer biology and to develop new methods for the prevention and treatment of cancer.

Kimmel Scholar Award

To select the grant recipients, the Sidney Kimmel Foundation for Cancer Research has created a Medical Advisory Board consisting of distinguished cancer researchers. Each year the Kimmel Foundation expects to select up to ten grant recipients who will receive $100,000 per year for two years. Qualified applicants must hold an M.D., Ph.D. or equivalent graduate degree and must perform research in an American not-for-profit institution during the period of Kimmel Foundation support.

The Kimmel Foundation is seeking accomplished young investigators dedicated to a career in cancer research. Applications are limited to those who achieved the equivalent rank of Assistant Professor on or after July, 2006. However, physicians who have both clinical and research responsibility are eligible if appointed on or after July, 2005. These awards are designed for researchers who do not yet have their own R01 funding. Applicants will be judged on the basis of quality of prior work, research proposed and letters of support. Funding of awards will be subject to execution of binding agreements setting forth terms and conditions under which scholarships will be provided. Applicants for 2010 awards will be notified by mid-April, 2010.

The Kimmel Translational Science Award

The Foundation provides up to five additional awards specifically for physicians engaged in translational science. Eligibility includes those with M.D. or equivalent degrees, who have achieved the rank of Assistant Professor on or after July, 2005. Candidates must not hold R01 funding for the laboratory component of their cancer research. Applicants must demonstrate a significant personal involvement in the laboratory component of the translational project described. The translational research may involve primarily animal studies but must include reasonable application to subsequent human investigation.

Week of August 31

American Cancer Society Funding Opportunities

Deadline: December 1, 2009
More Information

International Fellowships for Beginning Investigators (ACSBI)

The fellowships are funded by the American Cancer Society with the objective of fostering a bi-directional flow of knowledge, experience, expertise, and innovation between countries. These 12 month long fellowships are intended for beginning investigators and clinicians, who are in the early stages of their careers. Funding preference will be given to candidates who propose to conduct cancer research projects into the preclinical, clinical, epidemiology, psychosocial, behavioral, health services, health policy and outcomes and cancer control.

Eligible candidates should hold assistant professorships or similar positions at their home institutes and have at least two years of postdoctoral experience after obtaining their MD or Ph.D. degrees or equivalents. Awards are conditional on the return of the Fellow to the home institute at the end of the fellowship and on the availability of appropriate facilities and resources to apply the newly acquired skills. No extensions are permitted.

Between 6 - 8 Fellows are selected each year for awards with an average value of $45,000 for travel and stipend support. A competitive selection takes place once a year, based on the scientific review of the submitted material by an international panel of experts. Completed applications with all supporting documentation must reach UICC by the application closing date of December 1. Selection results are notified in mid-April the following year, and fellowships should be activated within 12 months of the date of the award.

Calculation of travel and stipend awards is based on the candidate's estimates, which are adjusted, if need be, to published fares and UICC scales. Travel awards contribute towards least expensive international two-way (return) air fares or other appropriate form of transport. Travel estimates should not include costs for internal travel within the home and/or host countries. These and extra costs for visa, passports, airport taxes, insurance, etc. are the responsibility of the Fellow. No allowances are made for accompanying dependents. The fellowship can be extended by 12 months, subject to the written approval of the home and host supervisors and at no additional cost to UICC.

Candidates who are physically present at the proposed host institute while their applications are under consideration are not eligible for UICC fellowships. Awards are subject to the UICC General Conditions for fellowships.

Week of August 17

American Association for Cancer Research--Scientific Achievement Awards

Deadline: November 16, 2009
More Information

AACR Award for Lifetime Achievement in Cancer Research

The AACR Award for Lifetime Achievement in Cancer Research was established and first given in 2004 to honor an individual who has made significant fundamental contributions to cancer research, either through a single scientific discovery or a body of work. These contributions, whether they have been in research, leadership, or mentorship, must have had a lasting impact on the cancer field and must have demonstrated a lifetime commitment to progress against cancer. The 7th Annual Award will be presented at the 2010 AACR Annual Meeting in Washington , DC , U.S.A. (April 17-21, 2010). The recipient must be present to receive the Award unles s otherwise unable to do so because of health restrictions or other serious conflicts. The recipient will receive an honorarium, a commemorative plaque, AACR Honorary membership, and support for the winner to attend the AACR Annual Meeting.

AACR Team Science Award

This Award has been established by the American Association for Cancer Research and Eli Lilly and Company to acknowledge and catalyze the growing importance of interdisciplinary teams to the understanding of cancer and/or the translation of research discoveries into clinical cancer applications. Proactive interaction between academic and industry researchers is particularly crucial to continue progress and accelerate drug development. The AACR Team Science Award will recognize an outstanding interdisciplinary research team for its innovative and meritorious science that has advanced or likely will advance our fundamental knowledge of cancer or a team that has applied existing knowledge to advance the detection, diagnosis, prevention, or treatment of cancer. The team selected to receive the 4th Annual AACR Team Science Award will collectively be awarded a prize of $50,000 and be recognized during the 2010 AACR Annual Meeting in Washington, DC, USA (April 17-21 2010). The representative institutions will be cited at the AACR Annual Meeting for their leadership role in fostering team science.

AACR Princess Takamatsu Memorial Lectureship

The AACR Princess Takamatsu Memorial Lectureship was established and first presented in 2007 in honor of the late Princess Takamatsu of Japan . During her extraordinary life, Her Imperial Highness Princess Takamatsu expended tremendous efforts toward the public and humanitarian cause of the eradication of cancer. She is regarded as an honored and respected figure in Japan , the United States , and within the international cancer research community as a whole. This Lectureship will recognize an individual scientist whose novel and significant work has had or may have a far-reaching impact on the detection, diagnosis, treatment, or prevention of cancer, and who embodies the dedication of the Princess to multinational collaborations. The recipient of the 3rd Annual Lectureship will present a major, 50-minute lecture during the AACR Annual Meeting 2010 in Washington DC, USA (April 17-21, 2010). The Lecturer will receive an unrestricted cash award of US$10,000, support to attend the AACR Annual Meeting, and a commemorative item serving as tangible witness to the singular honor of his/her selection.

 

Center for Cancer Research (CCR) Training Opportunity

More Information

The Center for Cancer Research (CCR) announces a training opportunity for physicians interested in dedicating their careers to clinical oncology research. The Clinical Investigator Development Program will link eligible clinicians to a vibrant, multidisciplinary research community of more than 250 talented CCR intramural scientists conducting cutting-edge research on the campuses of the National Institutes of Health (NIH) in Bethesda and Frederick , Maryland . The CCR is nationally recognized as a premier training ground for clinical research, which is conducted in the state-of-the-art Clinical Research Center . The program goal is to assist board-eligible/board-certified translational researchers to transition from a mentored position to independent investigator in either laboratory-based or patient-oriented research so that they will be highly competitive for tenure-track appointments in academia or comparable positions in government and industry. Further information on program objectives and provisions, requirements, eligibility, application and selection processes, and contact persons may be found in the attached flyer. 

American Association for Cancer Research -- Scientific Achievement Awards

Deadline: October, 2009
More Information

Awards included are The Richard and Hinda Rosenthal Foundation Award, Women in Cancer Resserach Charlotte Friend Memorial Lectureship, Joseph H. Burchenal Memorial Award, Minorities in Cancer Jane Cooke Wright Lectureship, ACS Award for Research Excellence in Cancer Epidemiology and Prevention, G.H.A. Clowes Memorial Award, Award for Outstanding Achievement in Chemistry in Cancer Research, and the Margaret Foti Award.